Siqi Wu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Siqi Wu has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
- Binbin Guo
Department of Genetics, School of Basic Medical Sciences, Suzhou Medical College of Soochow University, Suzhou, China
65 shared publications - Fanrong Li
Department of Genetics, Medical College of Soochow University, Suzhou, Jiangsu, China
65 shared publications - Jiachun Lu
School of public health, Guangzhou medical university, Guangzhou, China
65 shared publications - Jian Zheng
Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China and Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, China; Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, Nanjing, China; Affiliated Cancer Hospital and Institute of Guangzhou Medical University, Guangzhou, China
65 shared publications - Jieqiong Deng
Department of Genetics, Medical College of Soochow University, Suzhou, Jiangsu, China
65 shared publications - Jieyu Wang
Department of Genetics, Medical College of Soochow University, Suzhou, Jiangsu, China
65 shared publications
Latest Publications
- Open Access
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Data from Co-Targeting BCL-xL with MCL-1 Induces Lethal Mitochondrial Dysfunction in Diffuse Mesothelioma
Diffuse mesothelioma is a rare but highly aggressive and treatment-resistant neoplasm with low survival rates. Effective therapeutic strategies are limited, and resistance to treatment is a major obstacle. Myeloid cell leukemia (MCL)-1 and B-cell leukemia (BCL)-xL are antiapoptotic B-cell lymphoma 2 (Bcl-2) family proteins that block cell-intrinsic apoptosis through interactions on the mitochondrial outer membrane which contribute to therapeutic resistance. We investigated whether B-cell homology domain3 profiles were consistent between intra-patient fresh tumor sample, patient-derived cells, and patient-derived xenografts (PDX) by B-cell homology domain-3 profiling; we observed striking consistency which enabled cross-model comparisons. Next, we co-targeted BCL-xl and MCL-1 and noted that the combination synergistically reduced cell viability and increased apoptosis. Mechanistically, BCL-xL inhibition affected the cells through both the canonical and the emerging noncanonical apoptotic pathways. BCL-xL induced mitochondrial depolarization which resulted in MCL-1 cellular dependency, rendering cells highly sensitive to MCL-1 inhibition. Next, we co-targeted BCL-xL and MCL-1 in vivo which induced synthetic lethality in PDX models within hours, implying that this approach is not a safe strategy for clinical development. However, targeting MCL-1, which exerts its antiapoptotic activity without non-apoptotic on-target effects, decreased the mitochondrial threshold for apoptosis and enhanced chemosensitivity without toxicity in PDX models. Our findings suggest that targeting the mitochondria via MCL-1 enhances the efficacy of chemotherapy but co-targeting two proteins in the Bcl-2 pathways results in synergistic lethality. These results will help define a safe clinical strategy to utilize Bcl-2–targeted therapy to undermine therapeutic resistance in patients with diffuse mesothelioma.
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Co-Targeting BCL-xL with MCL-1 Induces Lethal Mitochondrial Dysfunction in Diffuse Mesothelioma
Diffuse mesothelioma is a rare but highly aggressive and treatment-resistant neoplasm with low survival rates. Effective therapeutic strategies are limited, and resistance to treatment is a major obstacle. Myeloid cell leukemia (MCL)-1 and B-cell leukemia (BCL)-xL are antiapoptotic B-cell lymphoma 2 (Bcl-2) family proteins that block cell-intrinsic apoptosis through interactions on the mitochondrial outer membrane which contribute to therapeutic resistance. We investigated whether B-cell homology domain3 profiles were consistent between intra-patient fresh tumor sample, patient-derived cells, and patient-derived xenografts (PDX) by B-cell homology domain-3 profiling; we observed striking consistency which enabled cross-model comparisons. Next, we co-targeted BCL-xl and MCL-1 and noted that the combination synergistically reduced cell viability and increased apoptosis. Mechanistically, BCL-xL inhibition affected the cells through both the canonical and the emerging noncanonical apoptotic pathways. BCL-xL induced mitochondrial depolarization which resulted in MCL-1 cellular dependency, rendering cells highly sensitive to MCL-1 inhibition. Next, we co-targeted BCL-xL and MCL-1 in vivo which induced synthetic lethality in PDX models within hours, implying that this approach is not a safe strategy for clinical development. However, targeting MCL-1, which exerts its antiapoptotic activity without non-apoptotic on-target effects, decreased the mitochondrial threshold for apoptosis and enhanced chemosensitivity without toxicity in PDX models. Our findings suggest that targeting the mitochondria via MCL-1 enhances the efficacy of chemotherapy but co-targeting two proteins in the Bcl-2 pathways results in synergistic lethality. These results will help define a safe clinical strategy to utilize Bcl-2–targeted therapy to undermine therapeutic resistance in patients with diffuse mesothelioma.
- Open Access
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from Co-Targeting BCL-xL with MCL-1 Induces Lethal Mitochondrial Dysfunction in Diffuse Mesothelioma
The BH3 profiles of DM patients showed similar activities in the tumor samples as well as the corresponding tumor sample derived cells.
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from Co-Targeting BCL-xL with MCL-1 Induces Lethal Mitochondrial Dysfunction in Diffuse Mesothelioma
The BH3 profiles of DM patients showed similar activities in the tumor samples as well as the corresponding tumor sample derived cells.
- Open Access
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 5 from Co-Targeting BCL-xL with MCL-1 Induces Lethal Mitochondrial Dysfunction in Diffuse Mesothelioma
Co-targeting MCL-1 and BCL-xL synergistically increase cell death through the intrinsic mitochondrial apoptotic pathway in PDC.
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 5 from Co-Targeting BCL-xL with MCL-1 Induces Lethal Mitochondrial Dysfunction in Diffuse Mesothelioma
Co-targeting MCL-1 and BCL-xL synergistically increase cell death through the intrinsic mitochondrial apoptotic pathway in PDC.
- Open Access
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 6 from Co-Targeting BCL-xL with MCL-1 Induces Lethal Mitochondrial Dysfunction in Diffuse Mesothelioma
BCL-xL inhibition does not change mitochondrial fusion and fission related proteins.
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 6 from Co-Targeting BCL-xL with MCL-1 Induces Lethal Mitochondrial Dysfunction in Diffuse Mesothelioma
BCL-xL inhibition does not change mitochondrial fusion and fission related proteins.
- Open Access
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Materials & Methods from Co-Targeting BCL-xL with MCL-1 Induces Lethal Mitochondrial Dysfunction in Diffuse Mesothelioma
Supplementary Materials & Methods
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Materials & Methods from Co-Targeting BCL-xL with MCL-1 Induces Lethal Mitochondrial Dysfunction in Diffuse Mesothelioma
Supplementary Materials & Methods
- Open Access
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Co-Targeting BCL-xL with MCL-1 Induces Lethal Mitochondrial Dysfunction in Diffuse Mesothelioma
Pathology evaluation of H&E slides for MPM188 tissue from the patient (Pt) and the PDX
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Co-Targeting BCL-xL with MCL-1 Induces Lethal Mitochondrial Dysfunction in Diffuse Mesothelioma
Pathology evaluation of H&E slides for MPM188 tissue from the patient (Pt) and the PDX
- Open Access
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Co-Targeting BCL-xL with MCL-1 Induces Lethal Mitochondrial Dysfunction in Diffuse Mesothelioma
Supplementary Table S4 from Co-Targeting BCL-xL with MCL-1 Induces Lethal Mitochondrial Dysfunction in Diffuse Mesothelioma
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Co-Targeting BCL-xL with MCL-1 Induces Lethal Mitochondrial Dysfunction in Diffuse Mesothelioma
Supplementary Table S4 from Co-Targeting BCL-xL with MCL-1 Induces Lethal Mitochondrial Dysfunction in Diffuse Mesothelioma
- Open Access
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Co-Targeting BCL-xL with MCL-1 Induces Lethal Mitochondrial Dysfunction in Diffuse Mesothelioma
Characterization of DM patient derived cell lines (PDC) and in vitro growth features.
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Co-Targeting BCL-xL with MCL-1 Induces Lethal Mitochondrial Dysfunction in Diffuse Mesothelioma
Characterization of DM patient derived cell lines (PDC) and in vitro growth features.